Taking a Closer Look at Nymox's 'Overinflated' Prostate Drug Hype

It's time for some truth-telling about Nymox (NYMX) after a week in which the drug maker's stock took a long hike up Cow Feces Mountain.

Nymox will not be successful convincing the U.S. Food and Drug Administration (or its counterpart in Europe) to approve fexapotide to treat men with enlarged prostates.

How do I know this? Because regulators don't approve new drugs that fail large clinical trials.

Back to news